Medicines, Supplements & Kidney Safety · VitaminsGamot, Supplement at Kaligtasan ng Bato · BitaminaTambal, Supplement ug Kaluwasan sa Kidney · BitaminaGamut, Supplement at Kaligtasan ning Batu · Bitamina

Vitamin B1 and Niacin in Kidney CareVitamin B1 at Niacin sa Pangangalaga sa BatoVitamin B1 ug Niacin sa Pag-atiman sa KidneyVitamin B1 at Niacin king Pamag-alaga king Batu

Spotting low vitamin B1 when eating fails, and why niacin pills no longer belong beside a statin.Pagkilala sa kakulangan ng vitamin B1 kapag hindi makakain, at kung bakit hindi na dapat isabay ang niacin na tableta sa statin.Pag-ila sa kakulang sa vitamin B1 kung dili makakaon, ug ngano nga dili na angay iuban ang niacin nga tableta sa statin.Pamakilala king kulang a vitamin B1 nung e makapangan, at nung bakit e na dapat isabay ing niacin a tableta king statin.

Summary

Thiamine. Suspect thiamine (vitamin B1) deficiency when intake has failed, including on dialysis, after bariatric surgery or with persistent vomiting on incretin therapy, and the patient has abdominal pain or unexplained hyperlactatemia. Draw whole-blood thiamine diphosphate if this causes no delay, then treat empirically, parenterally when Wernicke encephalopathy is possible.

Niacin. Added to statins, niacin raised high-density lipoprotein cholesterol (HDL-C) without reducing cardiovascular events in two outcome trials, and increased serious harms in the larger one.

Practice. For statin intolerance, choose ezetimibe, bempedoic acid or proprotein convertase subtilisin/kexin type 9 (PCSK9)-directed therapy by chronic kidney disease (CKD) stage, gout risk and access.

PublishedNailathalaGipatikPepalwal: ReferencesMga SanggunianMga TinubdanReng Reperensya: 22 Read timeOras ng pagbasaOras sa pagbasaOras ning pamamasa:
Last ReviewedHuling Na-reviewKatapusang Na-reviewKarinan Na-review:
A Filipino man in his fifties at a bright clinic desk holds up a vitamin bottle beside a phone photo of its label while reviewing his medicine list
💡

The one-minute answerAng sagot sa isang minutoAng tubag sa usa ka minutoIng sagot king metung a minutu

This guide is about two B vitamins that behave very differently. Vitamin B1 (thiamine) is a spark plug your cells need to burn food for energy. If you vomit for days, can barely eat, have had weight-loss surgery, or receive dialysis, your body can run low, and one surprising sign is stubborn belly pain with nausea. It is treatable, often quickly. Niacin (vitamin B3) pills were once used to improve cholesterol numbers. Large studies showed that adding niacin to a statin (the usual cholesterol medicine) did not prevent heart attacks or strokes and caused more side effects, so it is no longer a routine add-on. If statins bothered you, other proven medicines exist.Tungkol ang gabay na ito sa dalawang B vitamin na magkaiba ang kilos. Ang Vitamin B1 (thiamine) ay parang spark plug na kailangan ng mga cell para gawing enerhiya ang pagkain. Kung ilang araw kang nagsusuka, halos hindi makakain, naoperahan para pumayat, o nagda-dialysis, puwedeng maubos ito, at isang nakakagulat na senyales ang matagal na sakit ng tiyan na may pagduduwal. Nagagamot ito, kadalasan nang mabilis. Ang niacin (vitamin B3) na tableta ay dating ginagamit para gumanda ang numero ng cholesterol. Ipinakita ng malalaking pag-aaral na ang pagdagdag ng niacin sa statin (ang karaniwang gamot sa cholesterol) ay hindi nakaiwas sa atake sa puso o stroke at nagdulot ng mas maraming side effect, kaya hindi na ito karaniwang idinadagdag. Kung hindi mo nakayanan ang statin, may iba pang napatunayang gamot.Mahitungod kini nga giya sa duha ka B vitamin nga lahi kaayo ang batasan. Ang Vitamin B1 (thiamine) sama sa spark plug nga gikinahanglan sa mga cell aron himoong enerhiya ang pagkaon. Kung pila ka adlaw ka nang nagsuka, halos dili makakaon, naoperahan aron mogamay, o nagpa-dialysis, mahimong mahurot kini, ug usa ka katingalahang timaan ang dugay nga sakit sa tiyan nga adunay kasukaon. Matambalan kini, kasagaran dali ra. Ang niacin (vitamin B3) nga tableta kaniadto gigamit aron mamaayo ang numero sa cholesterol. Gipakita sa dagkong mga pagtuon nga ang pagdugang og niacin sa statin (ang naandang tambal sa cholesterol) wala makapugong sa atake sa kasingkasing o stroke ug nagpadaghan sa side effect, busa dili na kini naandan nga idugang. Kung wala nimo maagwanta ang statin, aduna pay laing napamatud-ang tambal.Tungkul ining giya king adwang B vitamin a magkaiba ing ugali. Ing Vitamin B1 (thiamine) antimo yang spark plug a kailangan dareng cell ban gawan dang enerhiya ing pamangan. Nung pilan nang aldo kang mumulua, ali ka makapangan, mi-opera ka ban mamalate, o mag-dialysis ka, malyari yang maubus, at metung a makagulat a tanda ing matagal a sakit ning atyan a atin pamagmulua. Malyari yang panulunan, kalambang masikan. Ing niacin (vitamin B3) a tableta dati yang gagamitan ban sumanting ing numeru ning cholesterol. Pepakit dareng maragul a pag-aral a ing pamamandagdag niacin king statin (ing karaniwan a gamut king cholesterol) e ya mekapigil king atake king pusu o stroke at mikayabe yang dakal a side effect, anya e ne karaniwan idagdag. Nung e me kayanan ing statin, atin pang aliwa a apatunayan a gamut.

⛔

Get urgent care nowMagpatingin agad sa emergencyPagpatan-aw dayon sa emergencyMagpatingin ka agad king emergency

Go to the emergency room if you or your family member has confusion, new trouble walking or keeping balance, double vision or jerky eye movements, fainting, severe or worsening belly pain, a racing heart with breathlessness or leg swelling, or cannot keep any food or fluids down. Tell the team about dialysis, recent weight-loss surgery, weight-loss injections, or days of vomiting, because low vitamin B1 can cause brain and heart problems that need treatment within hours.Pumunta sa emergency room kung ikaw o ang kapamilya mo ay may pagkalito, bagong hirap sa paglakad o pagbalanse, doble ang paningin o paggalaw-galaw ng mata, pagkahimatay, matindi o lumalalang sakit ng tiyan, mabilis na tibok ng puso na may hingal o pamamaga ng binti, o hindi makapagpanatili ng pagkain o inumin. Sabihin sa team kung nagda-dialysis, bagong naoperahan para pumayat, gumagamit ng weight-loss injection, o ilang araw nang nagsusuka, dahil ang kakulangan sa vitamin B1 ay puwedeng magdulot ng problema sa utak at puso na kailangang gamutin sa loob ng ilang oras.Adto sa emergency room kung ikaw o ang imong kapamilya adunay kalibog, bag-ong kalisod sa paglakaw o pagbalanse, doble nga panan-aw o pagkurog-kurog sa mata, pagkaluya o pagkawala sa panimuot, grabe o nagkagrabe nga sakit sa tiyan, paspas nga pitik sa kasingkasing nga adunay hangos o paghubag sa bitiis, o dili makapugong sa pagkaon o ilimnon. Ingna ang team kung nagpa-dialysis, bag-ong naoperahan aron mogamay, nagagamit og weight-loss injection, o pila ka adlaw nang nagsuka, kay ang kakulang sa vitamin B1 makahatag og problema sa utok ug kasingkasing nga kinahanglang tambalan sulod sa pipila ka oras.Munta ka king emergency room nung ika o ing kapamilya mu atin pamaglito, bayung kasakitan king paglakad o pamagbalanse, doble ing panulu o pamaggalo-galo ning mata, pamagkahimatay, malala o lalung malalang sakit ning atyan, masikan a pamitik ning pusu a atin pangisnawa o pamagbulkas ning bitis, o e makapagpanatili pamangan o inumin. Sabyan me ing team nung mag-dialysis ka, bayu kang mi-opera ban mamalate, gagamit weight-loss injection, o pilan nang aldo kang mumulua, uli ta ing kulang a vitamin B1 malyari yang manyabi problema king utak at pusu a kailangan panulunan king lub da ning pilan a oras.

Two B vitamins, two very different storiesDalawang B vitamin, dalawang magkaibang kuwentoDuha ka B vitamin, duha ka lahi kaayong istoryaAdwang B vitamin, adwang magkaibang kuwentu

Vitamins B1 and B3 sit side by side in a vitamin B-complex tablet, but in kidney care they raise opposite questions. With B1, the worry is having too little, quietly, when eating has gone badly. With B3, the question is whether taking large medicine doses helps the heart. It does not, for most people already on a statin.Magkatabi ang vitamin B1 at B3 sa isang B-complex na tableta, pero sa pangangalaga sa bato ay magkasalungat ang tanong nila. Sa B1, ang alalahanin ay ang kakulangan nang hindi napapansin, kapag hindi maayos ang pagkain. Sa B3, ang tanong ay kung nakakatulong ba sa puso ang pag-inom ng malalaking dosis na gamot. Hindi, para sa karamihan na umiinom na ng statin.Magtupad ang vitamin B1 ug B3 sa usa ka B-complex nga tableta, apan sa pag-atiman sa kidney magkasukwahi ang ilang pangutana. Sa B1, ang kabalaka mao ang kakulang nga dili mamatikdan, kung dili maayo ang pagkaon. Sa B3, ang pangutana kung makatabang ba sa kasingkasing ang pag-inom og dagkong dosis nga tambal. Dili, alang sa kadaghanan nga nag-inom na og statin.Magsiping ing vitamin B1 at B3 king metung a B-complex a tableta, oneng king pamag-alaga king batu magkasalungat ing kutang da. King B1, ing pamag-alala ing kakulangan a e apansinan, nung e masanting ing pamangan. King B3, ing kutang nung makatulung ya king pusu ing pamanainum maragul a dosis a gamut. Ali, para king karamihan a minum nang statin.

Two side-by-side panels: on the left a glowing cell powerhouse fed by vitamin B1 turning food into energy; on the right three labeled bottles showing food niacin, nicotinic acid medicine, and nicotinamide

Left: vitamin B1 helps cells turn food into energy. Right: vitamin B3 comes in three forms that do different things, from food to high-dose medicine.Kaliwa: tinutulungan ng vitamin B1 ang mga cell na gawing enerhiya ang pagkain. Kanan: ang vitamin B3 ay may tatlong anyo na magkakaiba ang gawa, mula sa pagkain hanggang sa mataas na dosis na gamot.Wala: gitabangan sa vitamin B1 ang mga cell nga himoong enerhiya ang pagkaon. Tuo: ang vitamin B3 adunay tulo ka porma nga lahi-lahi ang buhat, gikan sa pagkaon hangtod sa taas nga dosis nga tambal.Kayli: tutulungan ning vitamin B1 dareng cell ban gawan dang enerhiya ing pamangan. Wanan: ing vitamin B3 atin yang atlung anyu a magkakaiba ing gawa, manibat king pamangan anggang king maragul a dosis a gamut.

When the body runs low on vitamin B1Kapag nauubusan ng vitamin B1 ang katawanKung mahurotan og vitamin B1 ang lawasNung maubusan vitamin B1 ing katawan

Your body stores only a small amount of vitamin B1, so the supply can run down within weeks when you eat very little or keep vomiting. Cells then struggle to finish burning sugar, and a waste product called lactate can build up in the blood. The nerves and muscles of the gut need a lot of energy, which may be why some people develop belly pain, nausea, vomiting, and loss of appetite before anything else. Doctors call this gastrointestinal beriberi. It is uncommon, easy to miss because the symptoms look like many other stomach problems, and very treatable.Kaunti lang ang naiimbak na vitamin B1 sa katawan, kaya puwede itong maubos sa loob ng ilang linggo kapag kaunti ang kain o tuloy-tuloy ang pagsusuka. Nahihirapan ang mga cell na tapusin ang pagsunog ng asukal, at puwedeng dumami sa dugo ang tinatawag na lactate. Malaki ang kailangang enerhiya ng mga nerve at muscle ng bituka, kaya siguro may ilang tao na unang nagkakaroon ng sakit ng tiyan, pagduduwal, pagsusuka, at kawalan ng gana. Tinatawag ito ng mga doktor na gastrointestinal beriberi. Hindi ito karaniwan, madaling hindi mapansin dahil kamukha ng ibang sakit sa tiyan, at madaling gamutin.Gamay ra ang natipigang vitamin B1 sa lawas, busa mahimong mahurot kini sulod sa pipila ka semana kung gamay ang kaon o padayon ang pagsuka. Maglisod ang mga cell sa pagtapos sa pagsunog sa asukal, ug mahimong motaas sa dugo ang gitawag nga lactate. Dako ang enerhiyang gikinahanglan sa mga nerve ug muscle sa tinai, mao tingali nga ang ubang tawo unang makabati og sakit sa tiyan, kasukaon, pagsuka, ug kawalay gana. Gitawag kini sa mga doktor nga gastrointestinal beriberi. Dili kini kasagaran, dali nga dili mamatikdan kay susama sa ubang sakit sa tiyan, ug dali ra tambalan.Kakaunti mu ing makatagong vitamin B1 king katawan, anya malyari yang maubus king lub da ning pilan a dominggu nung kakaunti ing pamangan o tuloy-tuloy ing pamagmulua. Mairapan la reng cell ban tapusan ing pamanulu king asukal, at malyaring dumakal king daya ing aus dang lactate. Maragul ing kailangan a enerhiya dareng nerve at muscle ning bituka, anya siguru atin taung mumuna lang makaramdam sakit ning atyan, pamagmulua-mulua, pamagmulua, at kawalan gana. Aus de ini dareng doktor a gastrointestinal beriberi. E ya karaniwan, malagwa ya e mapansinan uli ta kamukha ne ing aliwang sakit ning atyan, at malagwa yang panulunan.

Who is at higher risk?Sino ang mas nanganganib?Kinsa ang mas peligro?Ninu ing mas delikadu?

Radial infographic with a vitamin B1 tank in the center draining toward six surrounding photos of situations that lower vitamin B1: dialysis, days of vomiting, weight-loss surgery, weight-loss injections, heavy alcohol use, and interrupted tube or vein feeding

Six situations that drain the body's small vitamin B1 store. If one of these is you, ask your care team about B1.Anim na sitwasyon na umuubos sa maliit na imbak ng vitamin B1 sa katawan. Kung isa rito ang sitwasyon mo, tanungin ang iyong care team tungkol sa B1.Unom ka sitwasyon nga makahurot sa gamay nga tipig sa vitamin B1 sa lawas. Kung usa niini ang imong kahimtang, pangutan-a ang imong care team bahin sa B1.Anam a sitwasyun a mamaubus king kakaunting tagu a vitamin B1 ning katawan. Nung metung kareni ing kalagayan mu, kutang me ing care team mu tungkul king B1.

Patient poster with three groups of warning signs of low vitamin B1: belly signs, brain and nerve signs, and heart signs, with an urgent triangle beside the brain and heart signs

Low vitamin B1 can show up in the belly first. New confusion, unsteady walking, eye problems, fainting, or breathlessness need emergency care.Puwedeng sa tiyan unang lumitaw ang kakulangan sa vitamin B1. Ang bagong pagkalito, pagsuray sa paglakad, problema sa mata, pagkahimatay, o hingal ay kailangan ng emergency na pangangalaga.Mahimong sa tiyan unang motungha ang kakulang sa vitamin B1. Ang bag-ong kalibog, pagkiay-kiay sa paglakaw, problema sa mata, pagkaluya, o hangos nagkinahanglan og emergency nga pag-atiman.Malyaring king atyan mumuna lumwal ing kulang a vitamin B1. Ing bayung pamaglito, pamagsuray king paglakad, problema king mata, pamagkahimatay, o pangisnawa kailangan emergency a pamag-alaga.

What your care team may doAno ang maaaring gawin ng iyong care teamUnsay mahimong buhaton sa imong care teamNanu ing malyaring gawan ning care team mu

1

Ask and examineMagtanong at magsuriMangutana ug mosusiMangutang at manyuri

Questions about vomiting, eating, weight loss, surgery, alcohol, dialysis, and new medicines; a check of the eyes, balance, and heart.Mga tanong tungkol sa pagsusuka, pagkain, pagpayat, operasyon, alak, dialysis, at bagong gamot; pagsuri sa mata, balanse, at puso.Mga pangutana bahin sa pagsuka, pagkaon, pagniwang, operasyon, alak, dialysis, ug bag-ong tambal; pagsusi sa mata, balanse, ug kasingkasing.Kutang tungkul king pamagmulua, pamangan, pamamalate, opera, alak, dialysis, at bayung gamut; pamagsuri king mata, balanse, at pusu.

2

Take blood first, if possibleKumuha muna ng dugo, kung kayaPagkuha una og dugo, kung mahimoMangua muna daya, nung malyari

A blood vitamin B1 level and a lactate level, drawn before the first dose when this does not delay care.Pagsukat ng vitamin B1 at lactate sa dugo, kinukuha bago ang unang dosis kung hindi ito makakaantala sa gamutan.Pagsukod sa vitamin B1 ug lactate sa dugo, kuhaon sa dili pa ang unang dosis kung dili kini makapadugay sa pagtambal.Pamagsukad vitamin B1 at lactate king daya, kukuanan bayu ing mumunang dosis nung e ya makaantala king panulu.

3

Start B1 without waitingSimulan ang B1 nang hindi naghihintaySugdan ang B1 nga dili maghulatMumpisa B1 a e maglaus

The result can take days. When the story fits, treatment usually starts right away, often by vein (IV) at first.Puwedeng ilang araw bago lumabas ang resulta. Kapag tugma ang kuwento, kadalasang sinisimulan agad ang gamot, madalas sa ugat (IV) muna.Mahimong pila ka adlaw una mogawas ang resulta. Kung motugma ang istorya, kasagaran sugdan dayon ang tambal, kasagaran sa ugat (IV) una.Malyaring pilan a aldo bayu lumwal ing resulta. Nung tugma ing kuwentu, kalambang pimpisan agad ing gamut, kalambang king ugat (IV) muna.

4

Restart food carefullyIbalik nang maingat ang pagkainIbalik nga mainampingon ang pagkaonIbalik a maingat ing pamangan

When eating restarts after a long gap, potassium, phosphate, and magnesium can drop. The team checks them and times blood tests around dialysis.Kapag muling kumain pagkatapos ng mahabang pagitan, puwedeng bumaba ang potassium, phosphate, at magnesium. Sinusuri ito ng team at itinatapat ang blood test sa oras ng dialysis.Kung mokaon na usab human sa dugay nga pagitan, mahimong mous-os ang potassium, phosphate, ug magnesium. Susihon kini sa team ug itakda ang blood test sa oras sa dialysis.Nung mangan neng pasibayu kaibat ning mabayang pagitan, malyaring tuknang ing potassium, phosphate, at magnesium. Suriyan da reti ning team at itapat de ing blood test king oras ning dialysis.

Many people feel better within a day or two of treatment, and the lactate level often falls. That improvement is reassuring, but your doctors will still look for other causes of belly pain, because more than one problem can be present at the same time. Do not start high-dose vitamin pills on your own to prevent this; if you are at risk, ask your kidney team whether a kidney-friendly multivitamin or a B1 supplement is right for you.Maraming gumagaan ang pakiramdam sa loob ng isa o dalawang araw ng gamutan, at kadalasang bumababa ang lactate. Nakakapanatag ang pagbuti, pero hahanapin pa rin ng doktor ang ibang sanhi ng sakit ng tiyan, dahil puwedeng higit sa isa ang problema nang sabay. Huwag basta uminom ng mataas na dosis na bitamina para umiwas dito; kung nanganganib ka, tanungin ang iyong kidney team kung bagay sa iyo ang kidney-friendly na multivitamin o B1 supplement.Daghan ang mamaayo ang pamati sulod sa usa o duha ka adlaw sa pagtambal, ug kasagaran mous-os ang lactate. Makapahupay ang pag-ayo, apan pangitaon gihapon sa doktor ang ubang hinungdan sa sakit sa tiyan, kay mahimong labaw sa usa ang problema dungan. Ayaw lang pag-inom og taas nga dosis nga bitamina aron malikayan kini; kung peligro ka, pangutan-a ang imong kidney team kung haom ba nimo ang kidney-friendly nga multivitamin o B1 supplement.Dakal ing gumaan ing pakiramdam king lub da ning metung o adwang aldo ning panulu, at kalambang tuknang ing lactate. Makapanatag ing pamagsanting, oneng anapan da pa murin dareng doktor ing aliwang sangkan ning sakit ning atyan, uli ta malyaring mayigit king metung ing problema king misan a oras. E ka basta uminum maragul a dosis a bitamina ban iwasan ini; nung delikadu ka, kutang me ing kidney team mu nung bagay keka ing kidney-friendly a multivitamin o B1 supplement.

Niacin pills and cholesterol: better numbers, not fewer heart attacksNiacin na tableta at cholesterol: gumanda ang numero, pero hindi nabawasan ang atake sa pusoNiacin nga tableta ug cholesterol: nindot ang numero, apan wala makunhod ang atake sa kasingkasingNiacin a tableta at cholesterol: sinanting ing numeru, oneng e mekunan ing atake king pusu

The niacin in rice, fish, chicken, peanuts, and mushrooms is a normal part of a healthy diet. High-dose niacin medicine (nicotinic acid, usually 1,000 to 2,000 mg a day) is different: it lowers triglycerides and raises HDL (high-density lipoprotein, the "good" cholesterol). Two large trials tested it in people already taking a statin. In the bigger one, about 132 of every 1,000 people on niacin had a heart attack, stroke, or blocked-artery procedure, compared with about 137 of every 1,000 on a dummy pill: a difference small enough to be chance. Niacin also caused more problems with blood sugar control, new diabetes, stomach upset, muscle problems, infections, and bleeding.Bahagi ng malusog na pagkain ang niacin sa kanin, isda, manok, mani, at kabute. Iba ang mataas na dosis na niacin na gamot (nicotinic acid, karaniwang 1,000 hanggang 2,000 mg bawat araw): pinabababa nito ang triglyceride at pinatataas ang HDL (high-density lipoprotein, ang "mabuting" cholesterol). Sinubukan ito ng dalawang malaking trial sa mga umiinom na ng statin. Sa mas malaki, mga 132 sa bawat 1,000 na nag-niacin ang nagkaroon ng atake sa puso, stroke, o operasyon sa baradong ugat, kumpara sa mga 137 sa bawat 1,000 na nasa dummy na tableta: napakaliit na pagkakaiba na puwedeng nagkataon lang. Nagdulot din ang niacin ng mas maraming problema sa kontrol ng asukal, bagong diabetes, sakit ng sikmura, problema sa muscle, impeksyon, at pagdurugo.Bahin sa himsog nga pagkaon ang niacin sa kan-on, isda, manok, mani, ug uhong. Lahi ang taas nga dosis nga niacin nga tambal (nicotinic acid, kasagaran 1,000 ngadto sa 2,000 mg matag adlaw): gipaubos niini ang triglyceride ug gipataas ang HDL (high-density lipoprotein, ang "maayong" cholesterol). Gisulayan kini sa duha ka dakong trial sa mga nag-inom na og statin. Sa mas dako, mga 132 sa matag 1,000 nga nag-niacin ang naatake sa kasingkasing, na-stroke, o naoperahan sa nabarang ugat, itandi sa mga 137 sa matag 1,000 nga nag-dummy nga tableta: gamay kaayong kalainan nga mahimong sulagma lang. Nagpadaghan usab ang niacin sa problema sa kontrol sa asukal, bag-ong diabetes, sakit sa tiyan, problema sa muscle, impeksyon, ug pagdugo.Bahagi ning masalusung a pamangan ing niacin king nasi, asan, manuk, mani, at kabuti. Aliwa ing maragul a dosis a niacin a gamut (nicotinic acid, karaniwan 1,000 anggang 2,000 mg balang aldo): pababan na ing triglyceride at pataasan na ing HDL (high-density lipoprotein, ing "mayap" a cholesterol). Sinubukan de ini dareng adwang maragul a trial kareng minum nang statin. King mas maragul, malapit 132 king balang 1,000 a minum niacin ing atakan king pusu, stroke, o mi-opera king mibara a ugat, kumpara king malapit 137 king balang 1,000 a minum dummy a tableta: makapale a pamagkaiba a malyaring nagkataun mu. Mikayabe ya murin ing niacin dakal a problema king kontrol ning asukal, bayung diabetes, sakit ning atyan, problema king muscle, impeksyun, at pamagdaya.

Three labeled containers comparing food niacin, high-dose nicotinic acid medicine, and nicotinamide, each with a short line about what it does and its main caution

Food niacin, high-dose nicotinic acid, and nicotinamide share a name but act differently. Only nicotinic acid changes cholesterol, and it causes flushing.Magkapangalan ang niacin sa pagkain, mataas na dosis na nicotinic acid, at nicotinamide, pero magkaiba ang gawa. Ang nicotinic acid lang ang nagbabago sa cholesterol, at nagdudulot ito ng pamumula ng balat.Magkapareha og ngalan ang niacin sa pagkaon, taas nga dosis nga nicotinic acid, ug nicotinamide, apan lahi ang buhat. Ang nicotinic acid ra ang mausab sa cholesterol, ug kini makapapula sa panit.Magkalagyu ing niacin king pamangan, maragul a dosis a nicotinic acid, at nicotinamide, oneng magkaiba ing gawa. Ing nicotinic acid mu ing magbayu king cholesterol, at manyabi yang pamamula ning balat.

Flushing (warm, red, itchy skin, often within an hour of a dose) is the side effect people notice first. Liver injury, higher blood sugar, gout flares, and muscle aches matter more. If you take niacin now, do not stop or start it on your own; bring it to your next visit so your doctor can review it with you.Ang pamumula ng balat (mainit, mapula, makating balat, kadalasan sa loob ng isang oras matapos uminom) ang unang napapansin. Mas mahalaga ang pinsala sa atay, pagtaas ng asukal, pag-atake ng gout, at pananakit ng muscle. Kung umiinom ka ngayon ng niacin, huwag itong itigil o simulan nang mag-isa; dalhin ito sa susunod mong check-up para masuri ninyo ng doktor.Ang pagpula sa panit (init, pula, katol nga panit, kasagaran sulod sa usa ka oras human moinom) ang unang mamatikdan. Mas importante ang kadaot sa atay, pagtaas sa asukal, pag-atake sa gout, ug kasakit sa muscle. Kung nag-inom ka karon og niacin, ayaw kini hunonga o sugdi nga ikaw ra; dad-a kini sa sunod nimong check-up aron masusi ninyo sa doktor.Ing pamamula ning balat (mapali, mayabang, makatel a balat, kalambang king lub da ning metung a oras kaibat uminum) ing mumuna mapansinan. Mas mayalaga ing kasiraan king ate, pamagtaas ning asukal, pamag-atake ning gout, at sakit ning muscle. Nung minum ka ngeni niacin, e me pundian o pimpisan a ika mu; darame king makatuking check-up mu ban suriyan yu ning doktor.

If statins bothered you, niacin is not the usual next stepKung hindi mo nakayanan ang statin, hindi niacin ang karaniwang susunod na hakbangKung wala nimo maagwanta ang statin, dili niacin ang naandang sunod nga lakangNung e me kayanan ing statin, e niacin ing karaniwang makatuking pamaglakad

Muscle aches on a statin are common and often have other causes. Many people can take a different statin, a lower dose, or a dose on alternate days. When a statin truly is not possible, doctors usually reach for medicines with proof that they prevent heart attacks and strokes, such as ezetimibe, bempedoic acid, or injectable PCSK9 (proprotein convertase subtilisin/kexin type 9) blockers, depending on your kidney function, other medicines, cost, and availability. In people with chronic kidney disease (CKD), keeping LDL (low-density lipoprotein, the "bad" cholesterol) down remains one of the best ways to protect the heart.Karaniwan ang pananakit ng muscle habang nag-i-statin at madalas ay may ibang sanhi. Marami ang puwedeng uminom ng ibang statin, mas mababang dosis, o dosis tuwing ikalawang araw. Kapag talagang hindi puwede ang statin, kadalasang pinipili ng doktor ang mga gamot na may patunay na nakakaiwas sa atake sa puso at stroke, gaya ng ezetimibe, bempedoic acid, o injectable na PCSK9 (proprotein convertase subtilisin/kexin type 9) blocker, depende sa kidney function mo, ibang gamot, gastos, at kung mayroon nito. Sa may chronic kidney disease (CKD), ang pagpapababa ng LDL (low-density lipoprotein, ang "masamang" cholesterol) ay isa pa rin sa pinakamahusay na paraan para protektahan ang puso.Kasagaran ang kasakit sa muscle samtang nag-statin ug kasagaran adunay laing hinungdan. Daghan ang makainom og laing statin, mas ubos nga dosis, o dosis matag ikaduhang adlaw. Kung dili gyud mahimo ang statin, kasagaran pilion sa doktor ang mga tambal nga adunay pamatuod nga makapugong sa atake sa kasingkasing ug stroke, sama sa ezetimibe, bempedoic acid, o injectable nga PCSK9 (proprotein convertase subtilisin/kexin type 9) blocker, depende sa imong kidney function, ubang tambal, gasto, ug kung anaa kini. Sa adunay chronic kidney disease (CKD), ang pagpaubos sa LDL (low-density lipoprotein, ang "daotang" cholesterol) usa gihapon sa labing maayong paagi aron mapanalipdan ang kasingkasing.Karaniwan ing sakit ning muscle kabang mag-statin at kalambang atin aliwang sangkan. Dakal ing malyaring uminum aliwang statin, mas mababang dosis, o dosis balang kaduang aldo. Nung talagang e malyari ing statin, kalambang pilinan dareng doktor ing gamut a atin patunay a makapigil king atake king pusu at stroke, antimo ing ezetimibe, bempedoic acid, o injectable a PCSK9 (proprotein convertase subtilisin/kexin type 9) blocker, depende king kidney function mu, aliwang gamut, gastus, at nung atin na. Kareng atin chronic kidney disease (CKD), ing pamamababa king LDL (low-density lipoprotein, ing "marok" a cholesterol) metung ya pa murin kareng pekamasanting a paralan ban protektan ing pusu.

Four-step path for statin side effects: check other causes, adjust the statin, add or switch to proven medicines such as ezetimibe, bempedoic acid or a PCSK9 injection, and keep LDL down; a small crossed-out niacin bottle sits off the path

If statins bother you, your doctor has other proven options. Niacin is not a substitute.Kung hindi mo nakayanan ang statin, may iba pang napatunayang opsyon ang doktor mo. Hindi pamalit ang niacin.Kung wala nimo maagwanta ang statin, aduna pay laing napamatud-ang kapilian ang imong doktor. Dili puli ang niacin.Nung e me kayanan ing statin, atin pang aliwang apatunayan a pamipilian ing doktor mu. E ya kapalit ing niacin.

LDL
Low-density lipoprotein ("bad" cholesterol)
PCSK9
Proprotein convertase subtilisin/kexin type 9
⚠️

Be careful with "natural" cholesterol productsMag-ingat sa mga "natural" na produkto para sa cholesterolPag-amping sa mga "natural" nga produkto para sa cholesterolMag-ingat kareng "natural" a produktu para king cholesterol

Over-the-counter niacin, red yeast rice, and other supplements are not recommended to lower cholesterol: their strength varies, their benefit is unproven, and some can harm the liver, muscles, or kidneys. Coenzyme Q10 has not been shown to prevent statin muscle aches.Hindi inirerekomenda ang over-the-counter na niacin, red yeast rice, at iba pang supplement para pababain ang cholesterol: iba-iba ang lakas, hindi napatunayan ang benepisyo, at may ilang puwedeng makapinsala sa atay, muscle, o bato. Hindi napatunayang nakakaiwas ang Coenzyme Q10 sa pananakit ng muscle dahil sa statin.Dili girekomendar ang over-the-counter nga niacin, red yeast rice, ug ubang supplement aron paubsan ang cholesterol: lahi-lahi ang kusog, wala mapamatud-i ang kaayohan, ug ang uban makadaot sa atay, muscle, o kidney. Wala mapamatud-i nga makapugong ang Coenzyme Q10 sa kasakit sa muscle tungod sa statin.E rerekomendan ing over-the-counter a niacin, red yeast rice, at aliwang supplement ban pababan ing cholesterol: iba-iba ing sikan, e apatunayan ing pakinabang, at atin malyaring manyira king ate, muscle, o batu. E apatunayan a makapigil ing Coenzyme Q10 king sakit ning muscle uli ning statin.

What to bring to a medicine or nutrition reviewAno ang dadalhin sa pagsusuri ng gamot o nutrisyonUnsay dad-on sa pagsusi sa tambal o nutrisyonNanu ing darang king pamagsuri king gamut o nutrisyun

Flat-lay of items a patient brings to a clinic visit: a supplement bottle, a phone photo of a label, a handwritten list of statins tried with dates, and a dialysis schedule card

Bring the bottles or label photos, your statin history, and your dialysis schedule. These details change what your doctor recommends.Dalhin ang mga bote o litrato ng label, ang kasaysayan mo sa statin, at ang iskedyul ng dialysis. Binabago ng mga detalyeng ito ang irerekomenda ng doktor.Dad-a ang mga botelya o litrato sa label, ang imong kasaysayan sa statin, ug ang iskedyul sa dialysis. Kini nga mga detalye makausab sa irekomendar sa doktor.Darame ing bote o litratu ning label, ing kasaysayan mu king statin, at ing iskedyul ning dialysis. Babayuan dareni a detalye ing irekomenda ning doktor.

Common questionsMga karaniwang tanongKasagarang pangutanaReng karaniwan a kutang

Should everyone on dialysis take extra vitamin B1?Dapat bang uminom ng dagdag na vitamin B1 ang lahat ng nagda-dialysis?Angay ba nga moinom og dugang vitamin B1 ang tanan nga nagpa-dialysis?Dapat nang uminum dagdag a vitamin B1 ding sablang mag-dialysis?
Not automatically. Many dialysis units prescribe a kidney-friendly multivitamin that contains B vitamins, especially for people who eat poorly. Ask your team; avoid unregulated high-dose products.Hindi awtomatiko. Maraming dialysis unit ang nagrereseta ng kidney-friendly na multivitamin na may B vitamins, lalo na sa mahina kumain. Tanungin ang team mo; iwasan ang mataas na dosis na produktong hindi rehistrado.Dili awtomatiko. Daghang dialysis unit ang nagreseta og kidney-friendly nga multivitamin nga adunay B vitamins, labi na sa huyang mokaon. Pangutan-a ang imong team; likayi ang taas nga dosis nga produkto nga dili rehistrado.E awtomatiku. Dakal a dialysis unit ing magreseta kidney-friendly a multivitamin a atin B vitamins, lalu na kareng mayna mangan. Kutang me ing team mu; iwasan ing maragul a dosis a produktung e rehistradu.
Can I get enough B1 from food?Makakakuha ba ako ng sapat na B1 sa pagkain?Makakuha ba ko og igong B1 sa pagkaon?Makakua ku pa sapat a B1 king pamangan?
Usually, if you are eating. Pork, fish, beans, and whole grains carry B1; polished white rice carries little. The problem in this guide is not eating, vomiting, or losses, which food alone cannot fix quickly.Kadalasan, kung nakakakain ka. May B1 ang baboy, isda, beans, at whole grains; kaunti lang sa pinakintab na puting bigas. Ang problema sa gabay na ito ay ang hindi pagkain, pagsusuka, o pagkawala, na hindi agad naaayos ng pagkain lang.Kasagaran, kung nakakaon ka. Adunay B1 ang baboy, isda, beans, ug whole grains; gamay ra sa gipasinaw nga puti nga bugas. Ang problema niini nga giya mao ang dili pagkaon, pagsuka, o pagkawala, nga dili dayon maayo sa pagkaon ra.Kalambang, nung makapangan ka. Atin B1 ing babi, asan, beans, at whole grains; kakaunti mu king pinakinang a maputing bigas. Ing problema kaniting giya ing e pamangan, pamagmulua, o pamagkawala, a e agad maayus ning pamangan mu.
Is the vitamin B3 in my B-complex tablet dangerous?Delikado ba ang vitamin B3 sa aking B-complex na tableta?Delikado ba ang vitamin B3 sa akong B-complex nga tableta?Delikadu ya ing vitamin B3 king B-complex ku a tableta?
The small amounts in ordinary multivitamins are not the same as cholesterol-lowering doses, which are dozens of times higher. Still, show every product to your kidney team.Ang maliit na dami sa karaniwang multivitamin ay hindi katulad ng dosis para sa cholesterol, na ilang dosenang beses na mas mataas. Gayunman, ipakita ang bawat produkto sa kidney team mo.Ang gamay nga kantidad sa naandang multivitamin dili pareho sa dosis para sa cholesterol, nga pila ka dosena ka pilo nga mas taas. Bisan pa, ipakita ang matag produkto sa imong kidney team.Ing kakaunti a dakal king karaniwan a multivitamin e ya kapareu ning dosis para king cholesterol, a pilan a dosenang besis a mas mataas. Pero, ipakit me ing balang produktu king kidney team mu.
I read that a niacin-like pill can lower phosphate on dialysis. Is that true?Nabasa ko na may pill na kahawig ng niacin na nagpapababa ng phosphate sa dialysis. Totoo ba?Nabasa nako nga adunay pill nga susama sa niacin nga makapaubos sa phosphate sa dialysis. Tinuod ba?Abasa ku a atin pill a kamukha ning niacin a mamababa phosphate king dialysis. Tutu ya?
Nicotinamide lowered phosphate a little for about six months in one large trial, but the effect faded by one year and it caused side effects such as low platelets and itching. It is not a routine treatment.Bahagyang pinababa ng nicotinamide ang phosphate nang mga anim na buwan sa isang malaking trial, pero nawala ang epekto pagdating ng isang taon at nagdulot ito ng side effect gaya ng mababang platelet at pangangati. Hindi ito karaniwang gamutan.Gamay nga gipaubos sa nicotinamide ang phosphate sulod sa mga unom ka bulan sa usa ka dakong trial, apan nawala ang epekto pag-abot sa usa ka tuig ug nagdala kini og side effect sama sa ubos nga platelet ug katol. Dili kini naandang pagtambal.Medyu pepababa ning nicotinamide ing phosphate king malapit anam a bulan king metung a maragul a trial, oneng mewala ing epektu pamakarating ning metung a banwa at mikayabe yang side effect antimo ing mababang platelet at pamangatel. E ya karaniwan a panulu.

Recognize thiamine deficiency early; retire niacin as a statin add-on

This guide pairs two water-soluble B vitamins that pose opposite problems in kidney care. Thiamine (vitamin B1) deficiency is a recognition problem: it is uncommon, but it is treatable, it can present first with abdominal pain, vomiting, anorexia and unexplained hyperlactatemia (gastrointestinal beriberi), and patients receiving dialysis carry several risk factors at once. Pharmacologic niacin (nicotinic acid) is a de-implementation problem: it improves high-density lipoprotein cholesterol (HDL-C) and triglycerides (TG), yet two large randomized trials found no reduction in cardiovascular events when it was added to statin therapy, with excess serious harm in the larger one. The 2026 American College of Cardiology/American Heart Association (ACC/AHA) multisociety dyslipidemia guideline lists niacin only as a last-line triglyceride-lowering option and directs statin-intolerant patients toward agents with outcome evidence.

1

Think of thiamine when intake has failed

Vomiting, anorexia, weight loss, bariatric surgery, alcohol, interrupted nutrition support, dialysis, or incretin-related intolerance, plus abdominal pain or a lactate that is not explained.

2

Draw blood, then treat without waiting

Whole-blood thiamine diphosphate before the first dose if it causes no delay; parenteral thiamine by protocol when Wernicke encephalopathy, cardiac beriberi or poor absorption is possible.

3

Reconcile niacin; reroute lipid care

Do not add niacin to a statin for prevention. Use a maximally tolerated statin, then ezetimibe, bempedoic acid or PCSK9-directed therapy as indicated and available.

Why thiamine deficiency raises lactate and stalls the gut

Mechanism figure of a cell: glucose to pyruvate in the cytoplasm, a thiamine diphosphate-dependent gate at pyruvate dehydrogenase into the mitochondrion, the Krebs cycle and ATP output; when the gate closes, pyruvate is diverted to lactate

Thiamine diphosphate is the cofactor that lets pyruvate enter the mitochondrion. Without it, pyruvate backs up into lactate and adenosine triphosphate (ATP) output falls, most in energy-hungry tissue such as brain, heart and gut muscle and nerve.

ATP
Adenosine triphosphate
TDP
Thiamine diphosphate
PDH
Pyruvate dehydrogenase
α-KGDH
α-Ketoglutarate dehydrogenase
LDH
Lactate dehydrogenase
NADH
Reduced nicotinamide adenine dinucleotide

Normal function. Ingested thiamine is absorbed in the proximal small bowel and phosphorylated intracellularly to thiamine diphosphate (TDP), the active coenzyme for pyruvate dehydrogenase (PDH), α-ketoglutarate dehydrogenase (α-KGDH), branched-chain α-keto acid dehydrogenase and transketolase. PDH is the gate between glycolysis and the tricarboxylic acid cycle; α-KGDH sits inside the cycle; transketolase links the pentose phosphate pathway to glycolysis and supplies reduced nicotinamide adenine dinucleotide phosphate for antioxidant defense (established physiology). Body stores are small and turnover is brisk, so stores can be depleted within weeks of poor intake.

What deficiency breaks. When TDP falls, PDH flux falls first in practice. Pyruvate accumulates and is reduced to lactate in the cytosol, regenerating NAD+ (nicotinamide adenine dinucleotide) so glycolysis can continue at low ATP yield. The result is a type B hyperlactatemia that occurs without hypoperfusion, and that a carbohydrate load worsens because it drives more substrate into a blocked gate. Tissues with high, continuous oxidative demand fail first: the brain (Wernicke encephalopathy), the myocardium and vascular tone (high-output cardiac beriberi), and peripheral nerves. The mechanism for the gastrointestinal phenotype is less well defined; energy failure of the enteric nervous system and smooth muscle, with dysmotility, is the leading explanation (mechanistic hypothesis).

Why kidney patients are exposed. Thiamine is small and water-soluble, so it crosses dialysis membranes; reduced appetite, dietary restriction, gastroparesis, intercurrent illness and loop diuretics (urinary loss before kidney failure) add to the deficit. A 2025 single-center hemodialysis study measured whole-blood thiamine by high-performance liquid chromatography and found deficiency in 11.5% of 113 patients, with lower levels associated with lower hemoglobin. This was a cross-sectional association, not a measure of incidence or causation. The 2026 review of thiamine in hospitalized patients also notes that sepsis, loop diuretics and malabsorption shift the risk upward.

Minimal line-art sigil: a small gold droplet representing the body's thiamine pool at the center, with the gut feeding it, the kidneys and dialysis draining it, and the brain and heart drawing on it, connected by dotted curved arrows

One small thiamine pool: the gut fills it, urine and dialysis drain it, and the brain, heart and gut wall draw on it. When intake fails and losses continue, the tissues with the highest demand fail first.

B1
Vitamin B1 (thiamine)

Gastrointestinal beriberi: the case, the history, and the 2026 signals

🔬

Opening case (2026) Case / mechanistic

A 67-year-old man receiving intermittent hemodialysis had chronic abdominal pain, nausea, vomiting and anorexia refractory to conventional therapy. Lactate was elevated and plasma thiamine was low before supplementation. Symptoms and lactate resolved rapidly after intravenous thiamine. One case teaches recognition and reassessment; it cannot establish incidence, a dialysis-specific cause, or a dose.

Take the nutrition history as a risk inventory. Ask for the duration and severity of vomiting and reduced intake, weight lost, prior bariatric or other gastrointestinal surgery, malabsorption, alcohol use, interrupted enteral or parenteral nutrition, dialysis modality and appetite, loop diuretic use, and the timing of any glucagon-like peptide-1 receptor agonist (GLP-1 RA) or dual incretin start or dose escalation. Then connect the risk to the physiology: a lactate that is high without shock, sepsis or metformin, in someone who has not been eating, is the bedside clue that makes the diagnosis worth testing for and treating.

SourceWhat it foundHow to use it
Hemodialysis case, 2026 Case / mechanisticCompatible symptoms, elevated lactate, low plasma thiamine, rapid response to IV thiamine in one patientRecognition template; no incidence or dosing inference
Systematic review of Wernicke encephalopathy in kidney disease, 2024 Observational46 published cases with acute or chronic kidney disease; prodromal loss of appetite, vomiting, weight loss, abdominal pain and diarrhea; recovery often followed high-dose parenteral thiamine, while Korsakoff syndrome appeared in those given low dosesTreat gastrointestinal prodrome as a window before neurologic injury; case-level evidence subject to reporting bias
GLP-1 RA pharmacovigilance and literature review, 2026 Observational15 cases of Wernicke encephalopathy (13 in the Food and Drug Administration Adverse Event Reporting System, FAERS); semaglutide 8 and tirzepatide 6; gastrointestinal symptoms or nutritional compromise in 13 of 15; disproportional reporting (reporting odds ratio 2.35, 95% CI 1.38–4.01); long-term neurologic sequelae in 7 of 11 with follow-upAsk about persistent vomiting and intake on incretin therapy; signal only, cannot establish incidence or causation
Pediatric report, 2026 Case / mechanisticEight-year-old with abdominal pain, food refusal, weight loss and rising lactate on thiamine-free parenteral nutrition; resolved within 24 hours of IV thiamineTeaching sidebar only; adult pathways here are not for pediatric use
Hemodialysis status study, 2025 ObservationalWhole-blood thiamine deficiency in 11.5% of 113 patients; association with hemoglobinDeficiency is not rare in dialysis; prevalence will vary by population and assay

CI, confidence interval. Evidence labels reflect study design; case reports and spontaneous reports describe what can happen, not how often.

Escalate first, then work the differential in parallel

Escalate immediately for hemodynamic instability, peritonism, severe or rising lactate, altered mental status, ataxia, nystagmus or ophthalmoplegia, or new heart failure or shock. Possible Wernicke encephalopathy or cardiac beriberi warrants protocol-based parenteral thiamine without delay, given before or with glucose where emergency hypoglycemia treatment allows. Treating hypoglycemia always comes first; do not withhold glucose from a hypoglycemic patient while thiamine is prepared. The European Federation of Neurological Societies (EFNS) guideline advises measuring total blood thiamine immediately before administration, using magnetic resonance imaging (MRI) to support the diagnosis, and suspecting Wernicke encephalopathy in every condition that can cause thiamine deficiency, not only alcohol use.

Do not missWhy it matters hereFirst moves
Sepsis and hypoperfusionThe common cause of type A hyperlactatemia; thiamine deficiency can coexistCultures, perfusion assessment, early antibiotics as indicated
Mesenteric ischemiaPain out of proportion and a high lactate in vascular patients, including on dialysis with intradialytic hypotensionUrgent computed tomography angiography and surgical review
Obstruction, pancreatitis, perforationVomiting and pain overlap fullyImaging, lipase, surgical review
Medication and toxin causesMetformin accumulation in low kidney function, alcohols, linezolid, nucleoside analogsMedication review; toxin screen and osmolar gap when indicated
Peritonitis in peritoneal dialysisCloudy effluent and abdominal painEffluent cell count, Gram stain and culture
Wernicke encephalopathy or cardiac beriberiNeurologic injury can become permanent; high-output failure can be fatalParenteral thiamine by protocol now; neurology or cardiology review
Portrait clinical algorithm: risk and compatible symptoms lead to red-flag screening; red flags route to emergency care and parenteral thiamine; otherwise draw whole-blood thiamine diphosphate and lactate, start thiamine without waiting, evaluate other causes in parallel, and reassess symptoms, lactate and neurologic status

A recognition pathway: screen for red flags first, draw blood before the first dose when that causes no delay, start thiamine without waiting for the result, and keep looking for other causes.

TDP
Thiamine diphosphate
IV
Intravenous
WE
Wernicke encephalopathy
PD
Peritoneal dialysis

Test before the first dose, treat on suspicion, and reassess deliberately

Testing. Whole-blood (erythrocyte) TDP reflects tissue status better than plasma thiamine, which falls quickly with recent intake and rises within hours of any dose. Collect the sample before replacement when it is immediately available, but never delay treatment for it: send-out turnaround is often days, and a normal result after supplementation is uninterpretable. Pair it with serial lactate, glucose, phosphate, magnesium and potassium, and document neurologic and hemodynamic status at baseline.

Treatment on suspicion. When suspicion is high, start empiric thiamine. Use the parenteral route for severe illness, unreliable absorption (vomiting, short bowel, recent bariatric surgery), or possible Wernicke encephalopathy, then transition to oral therapy when intake and absorption are reliable. Thiamine is dialyzable, so time doses after hemodialysis on dialysis days when practical. Record the time of each dose and of each reassessment; improvement in pain, nausea and lactate after thiamine supports the diagnosis but must be read beside concurrent fluids, antiemetics, nutrition and treatment of other causes.

IndicationWhat published sources describeEvidence
Suspected or manifest Wernicke encephalopathyEFNS: 200 mg three times daily, preferably IV, given before any carbohydrate (Level C). Kidney-disease case review: 500 mg IV three times daily often preceded full recoveryGuideline / consensus Observational
Refeeding-syndrome prophylaxis (adults)American Society for Parenteral and Enteral Nutrition (ASPEN): 100 mg before feeding or dextrose-containing IV fluids, then 100 mg daily for 5–7 days or longer in selected high-risk patients. Australasian Society of Parenteral and Enteral Nutrition (AuSPEN): thiamine before nutrition starts and daily for the first 7–10 days (Level B); doses in the studies reviewed ranged from 100 to 300 mg, and no study isolated thiamine's preventive effectGuideline / consensus
After bariatric surgeryEFNS: follow thiamine status for at least 6 months (Level B); parenteral supplementation (good practice point)Guideline / consensus
Hospitalized patients generally2026 clinical review: dose, route and duration vary by indication and guideline; framework by indication rather than one universal doseGuideline / consensus
⚠️

Use your institutional protocol

The table reports what each source states; it is not a substitute for a local order set. Pharmacy and the responsible clinical service should confirm indication, route, frequency, duration and oral transition, including timing around dialysis. Thiamine has a wide safety margin, and the EFNS guideline rates its overall safety as very good (Level B); rare anaphylaxis with IV use is the main caution.

Refeeding: separate prophylaxis from treatment, and read electrolytes against the dialysis clock

Timeline infographic across five days of refeeding: thiamine before the first feed, staged nutrition advance, daily phosphate, potassium and magnesium checks, with markers showing whether each blood sample was drawn before or after a dialysis session

Refeeding care on a timeline: thiamine before feeding, a planned nutrition advance, and daily electrolyte checks, each labeled as drawn before or after dialysis so a post-dialysis fall is not mistaken for refeeding.

HD
Hemodialysis
PO₄
Phosphate
K
Potassium
Mg
Magnesium

Mechanism. After prolonged starvation, carbohydrate reintroduction raises insulin, which drives phosphate, potassium and magnesium into cells and accelerates thiamine use as glycolytic flux resumes. Intracellular phosphate is consumed in phosphorylated intermediates and ATP synthesis. In a patient whose stores are already low, the serum concentration falls and thiamine-dependent enzymes fail at the moment demand rises (established physiology).

Definitions. The ASPEN consensus grades refeeding syndrome by the fall in serum phosphorus, potassium and/or magnesium within 5 days of reintroducing calories: 10%–20% (mild), 20%–30% (moderate), and more than 30% or organ dysfunction from these falls or from thiamine deficiency (severe). The 2025 AuSPEN consensus adds that actual refeeding syndrome is rare, should be diagnosed only once intake reaches at least 50% of estimated requirements, that thiamine, a multivitamin and regular electrolyte monitoring should be given to everyone at risk, and that there is no evidence that at-risk patients need a slower enteral start, with goal rates reached within 24–72 hours.

The dialysis twist. Hemodialysis removes phosphate and potassium, and a sample drawn after a session can show a large fall that has nothing to do with refeeding. Conversely, a patient on dialysis may start with high predialysis phosphate and potassium, masking depletion of intracellular stores. Compare like with like: predialysis with predialysis, and annotate every value with its timing relative to dialysis and to the nutrition restart. Treat emergency hypoglycemia immediately. Agree replacement thresholds and dialysate prescription with the renal and nutrition teams, because replacing phosphate or potassium aggressively in kidney failure carries its own risk. AuSPEN makes the same point: in kidney failure, preventive electrolyte dosing is hard to calculate from already-high levels and should involve the treating specialists.

Start with reconciliation: food niacin, nicotinic acid, and nicotinamide are different exposures

ExposureTypical amountPhysiologyClinical relevance
Dietary vitamin B3 (niacin equivalents from food, including tryptophan conversion)Milligrams per dayPrecursor of NAD+ and NADP+, the redox cofactors of energy metabolismDeficiency (pellagra) is rare; food intake is not a lipid therapy
Pharmacologic nicotinic acid (immediate-, sustained- or extended-release)Gram doses (500–2,000 mg/day)Activates hydroxycarboxylic acid receptor 2 (HCA2, also called GPR109A) on adipocytes, reducing lipolysis and free fatty acid flux to the liver; reduces hepatic TG esterification; raises HDL-CLowers TG and modestly lowers low-density lipoprotein cholesterol (LDL-C); prostaglandin D2-mediated flushing, hepatotoxicity (most with sustained-release), insulin resistance, hyperuricemia and gout, myopathy with statins
Nicotinamide (niacinamide)Hundreds of milligrams to gramsNo HCA2 activity, so no lipid effect and little flushing; reduces intestinal sodium-dependent phosphate transportInvestigated as a phosphate-lowering add-on in dialysis (NOPHOS); not a lipid drug

Record the indication, product name, dose, release formulation and co-therapies. Patients often call any of these "vitamin B3," and over-the-counter products may be labeled by either name. When current pharmacologic niacin use is found, review flushing, liver enzymes, glycemic control, urate and gout, and muscle symptoms, then decide with the patient whether there is any remaining indication.

The statin add-on question: lipids moved, events did not

Clinician infographic with two columns: on the left HDL cholesterol rising and triglycerides falling on niacin; on the right event bars for niacin and placebo that are nearly equal in two large trials, with a harms strip below

Niacin improved HDL cholesterol and triglycerides in both trials, but major vascular events were nearly identical to placebo, and serious harms rose in the larger trial.

HDL-C
High-density lipoprotein cholesterol
TG
Triglycerides

The hypothesis. Low HDL-C and high TG mark residual risk on statins, so raising one and lowering the other should prevent events. Two trials tested this on modern statin backgrounds.

AIM-HIGH (2011) RCT

Population
3,414 adults with established atherosclerotic cardiovascular disease (ASCVD), low HDL-C and elevated TG, on simvastatin ± ezetimibe to an LDL-C of 40–80 mg/dL
Intervention
Extended-release niacin 1,500–2,000 mg/day vs placebo
Lipids
HDL-C 35 → 42 mg/dL; TG 164 → 122 mg/dL at 2 years
Primary
16.4% vs 16.2%; hazard ratio (HR) 1.02 (95% CI 0.87–1.21); stopped early for futility at a mean 3 years

HPS2-THRIVE (2014) RCT

Population
25,673 adults with vascular disease after a run-in that standardized statin therapy and excluded niacin-intolerant participants
Intervention
Extended-release niacin 2 g plus laropiprant 40 mg vs placebo; median 3.9 years
Lipids
LDL-C 10 mg/dL lower and HDL-C 6 mg/dL higher on average
Primary
13.2% vs 13.7%; rate ratio 0.96 (0.90–1.03)
Serious harms
Diabetes control disturbance +3.7 points (number needed to harm, NNH, about 27); new diabetes +1.3 (NNH about 77); infection +1.4 (about 71); gastrointestinal +1.0 (100); musculoskeletal +0.7; bleeding +0.7 (about 143); skin +0.3

Interpretation. Both trials changed the surrogate in the expected direction without changing the outcome, the textbook pattern that separates biomarker improvement from clinical benefit. HPS2-THRIVE tested niacin with laropiprant, a prostaglandin D2 receptor antagonist added to blunt flushing, so its harms belong to that combination; AIM-HIGH, without laropiprant, also showed no benefit. Critics note that both enrolled patients with well-controlled LDL-C and that older trials without statins suggested benefit; that history explains why niacin was plausible, but it does not rescue it as an add-on to contemporary statin therapy. The 2026 ACC/AHA guideline's drug table states that cardiovascular outcome trials show no reduction in events when niacin is added to statins in secondary prevention, positions it as a last-line agent for severe hypertriglyceridemia because of intolerable side effects, and lists increased insulin resistance, frequent flushing and significant hepatotoxicity. The same guideline recommends against dietary supplements to lower LDL-C or TG and rates routine coenzyme Q10 for statin-associated muscle symptoms as 3: No Benefit (B-R).

🧪

CKD signal from AIM-HIGH Post hoc RCT subgroup

A post hoc analysis of 505 participants with stage 3 chronic kidney disease (CKD) found no cardiovascular benefit (primary endpoint 23.6% vs 23.9%; HR 1.02, 0.71–1.45) and no difference in estimated glomerular filtration rate (eGFR) change, but higher all-cause mortality on niacin (15.4% vs 8.9%; HR 1.73, 1.03–2.89), mostly from non-cardiovascular causes, with more discontinuation (32.7% vs 22.7%). Treat the mortality finding as an exploratory subgroup signal, not proof of harm; it reinforces, rather than creates, the case against niacin in CKD.

Absolute effects explorer: what the trials mean per 1,000 people

Relative effects hide the size of a benefit. This tool converts each trial's published arm proportions into events per 1,000 people over the trial's own follow-up. It uses crude event proportions from the primary publications, shows the published effect estimate separately, and should not be used to compare trials with different endpoints, populations or durations, or to predict an individual's risk.

ArmEvents per 1,000Source counts

Number needed to treat (NNT) = 1 ÷ absolute risk reduction, shown only where the published effect excludes no difference. CLEAR Outcomes and SHARP are included as the outcome-proven comparators for statin intolerance and CKD; they test different drugs and populations from the niacin trials.

Statin intolerance: confirm it, then choose an outcome-proven alternative

Ask about the timing of symptoms relative to starting or increasing the statin, their severity and distribution, creatine kinase (CK) if measured, interacting drugs, hypothyroidism and vitamin D status, prior agents and doses, and the response to withdrawal and rechallenge where appropriate. Many patients tolerate a different statin, a lower dose, or alternate-day dosing. Severe hypertriglyceridemia belongs on a separate pancreatitis-prevention pathway.

CLEAR Outcomes (2023) RCT

Population
13,970 statin-intolerant patients with, or at high risk of, cardiovascular disease
Intervention
Bempedoic acid 180 mg/day vs placebo; median 40.6 months
LDL-C
29.2 mg/dL greater reduction at 6 months (21.1 percentage points)
Primary
11.7% vs 13.3% four-component major adverse cardiovascular events (MACE); HR 0.87 (0.79–0.96); about 16 fewer events per 1,000 (NNT about 64)
Harms
Gout 3.1% vs 2.1%; cholelithiasis 2.2% vs 1.2%; small rises in creatinine, uric acid and hepatic enzymes

SHARP (2011) RCT

Population
9,270 patients with CKD (3,023 on dialysis) and no prior myocardial infarction or coronary revascularization
Intervention
Simvastatin 20 mg plus ezetimibe 10 mg vs placebo; median 4.9 years
Primary
Major atherosclerotic events 11.3% vs 13.4%; rate ratio (RR) 0.83 (0.74–0.94); about 21 fewer per 1,000 (NNT about 48)
Safety
Excess myopathy 2 per 10,000 patient-years; no excess hepatitis, gallstones or cancer

Bempedoic acid raises uric acid and creatinine slightly, a relevant trade-off in CKD and gout; verify renal eligibility, interactions and local availability before choosing it. Ezetimibe is the outcome-tested partner for a statin in CKD (SHARP). PCSK9 (proprotein convertase subtilisin/kexin type 9)-directed therapy is an option where cost and access allow. The 2026 ACC/AHA guideline names ezetimibe, bempedoic acid and PCSK9 monoclonal antibodies as the main nonstatin options; niacin is not among them.

Who with CKD should receive LDL-lowering therapy: two guideline frames

Two guideline families frame eligibility. Kidney Disease: Improving Global Outcomes (KDIGO) bases statin use in CKD on age, eGFR and dialysis or transplant status and does not use LDL-C targets; the 2026 ACC/AHA guideline uses risk categories, Predicting Risk of cardiovascular disease EVENTs (PREVENT) estimates and restored LDL-C goals. They agree on the core: most adults with non-dialysis CKD should be on LDL-lowering therapy.

GroupKDIGO2026 ACC/AHA
Age ≥50 years, eGFR <60 mL/min/1.73 m², not on chronic dialysis, no transplantStatin or statin–ezetimibe (1A in both the KDIGO 2013 lipid guideline and KDIGO 2024)LDL-lowering therapy for primary prevention in adults 40–75 years with CKD stage 3 or 4, regardless of LDL-C; Predicting Risk of cardiovascular disease EVENTs (PREVENT) equations, which include eGFR, for others aged 30–79
Age 18–49 years with CKDStatin if known coronary disease, diabetes, prior ischemic stroke or high estimated 10-year risk (2A)
Chronic dialysisDo not initiate a statin or statin–ezetimibe in most (2A); continue if already taking at dialysis start (2C)No dialysis-specific initiation recommendation in the guideline's published summaries; individualize (SHARP's dialysis subgroup was underpowered on its own)
Kidney transplantStatin suggested (2B)Follow transplant-specific guidance and interactions with calcineurin inhibitors
Established ASCVDSecondary prevention pathway with intensity and LDL-C goals per guideline; CKD raises absolute risk

KDIGO grades use its own system (1 = recommend, 2 = suggest; A–D = certainty) and are not interchangeable with ACC/AHA class and level. The PREVENT equations were derived and calibrated in US cohorts; label results accordingly when used for Filipino patients. Selected recommendations only; read the full guidelines for complete criteria.

Clinician reference card mapping LDL-lowering eligibility in CKD by age, eGFR, chronic dialysis, kidney transplant and established ASCVD, comparing KDIGO and 2026 ACC/AHA framing

Two guideline frames on one card. Most adults with non-dialysis CKD qualify for LDL-lowering therapy; on chronic dialysis, the question is whether to start, not whether to continue. The ACC/AHA dialysis cell is this guide's reading, as the published summaries carry no dialysis-specific recommendation.

ASCVD
Atherosclerotic cardiovascular disease
CKD
Chronic kidney disease
eGFR
Estimated glomerular filtration rate
KDIGO
Kidney Disease: Improving Global Outcomes
ACC/AHA
American College of Cardiology/American Heart Association
LDL
Low-density lipoprotein
PREVENT
Predicting Risk of cardiovascular disease EVENTs

CKD-specific niacin data. A 2026 target-trial emulation in 68,073 US veterans with incident CKD compared 2,005 niacin initiators with 62,866 statin initiators. Major adverse kidney events (MAKE: a sustained ≥57% eGFR decline, sustained eGFR <15 mL/min/1.73 m², incident end-stage kidney disease or death) did not differ (HR 0.96, 0.89–1.04; median 3.69 years), and eGFR slope did not differ significantly. Fibrate initiators had a slightly slower 10-year eGFR decline (0.26 mL/min/1.73 m² per year). Observational This shows no detectable kidney or death advantage for niacin over statins; it cannot establish cardiovascular equivalence, and confounding by indication is likely.

Nicotinamide for phosphate: an early effect that did not last

Mechanism. Nicotinamide reduces sodium-dependent phosphate transport in the intestine, a target distinct from the binders that complex dietary phosphate in the gut lumen (mechanistic rationale with human pharmacodynamic support).

NOPHOS (52-week results, 2023) RCT

Population
Maintenance hemodialysis with hyperphosphatemia; intention-to-treat 539 vs 183
Intervention
Modified-release nicotinamide 250–1,500 mg/day vs placebo, added to phosphate binders
Result
Serum phosphate −0.39 mg/dL at week 24 (−0.66 to −0.13); −0.08 mg/dL at week 52 (−0.36 to 0.20). Effect smaller with high baseline intact parathyroid hormone (PTH); larger in adherent patients
Safety
More thrombocytopenia, pruritus, anemia and diarrhea; herpes zoster only in the nicotinamide arm
Chart of the NOPHOS trial: the difference in serum phosphate between nicotinamide and placebo was −0.39 mg/dL at week 24 with a confidence interval below zero, and −0.08 mg/dL at week 52 with an interval crossing zero, beside a list of safety signals

The phosphate difference versus placebo was clear at 24 weeks but its confidence interval crossed zero by 52 weeks, while new safety signals appeared.

Phosphate is a surrogate; no trial has shown that nicotinamide improves patient outcomes. With waning efficacy, new safety signals and pill burden, it is not a routine option in CKD–mineral and bone disorder (CKD-MBD) care.

Dietary niacin and terminal metabolites: research, not targets

Two observational lines point in apparently opposite directions, and both are hypothesis-generating. In a metabolomics study, circulating N1-methyl-4-pyridone-3-carboxamide (4PY), a terminal metabolite of excess niacin, was associated with 3-year major adverse cardiovascular events in two validation cohorts (highest vs lowest quartile, adjusted HR 1.89, 1.26–2.84 and 1.99, 1.26–3.14; attenuated but still present after adding eGFR, HR 1.64 and 1.67), and 4PY, not its isomer N1-methyl-2-pyridone-5-carboxamide (2PY), induced vascular cell adhesion molecule 1 (VCAM-1) expression and leukocyte adhesion experimentally. Observational Case / mechanistic Separately, in National Health and Nutrition Examination Survey (NHANES) adults with CKD, the highest quartile of reported dietary niacin (>27.7 mg/day) was associated with lower prevalent cardiovascular disease (odds ratio 0.71, 0.56–0.90) and lower cardiovascular mortality (HR 0.61, 0.48–0.77) than the lowest. Observational

These are different exposures. Dietary recall measures food intake and carries healthy-eater confounding; 4PY reflects the metabolic handling of excess niacin and accumulates when kidney clearance falls, so part of its signal may track reduced kidney function, although adjustment for eGFR did not remove it. No clinical threshold, no dietary target and no change in management follows from either study. Keep food intake, circulating metabolites and gram-dose therapy distinct when counseling.

Applying this in Philippine practice

Clinical pearls

Six decision points
1
Hyperlactatemia without shock in a patient who has not been eating is thiamine deficiency until proven otherwise, and the treatment is cheap and safe.
2
Thiamine before or with glucose in at-risk patients, but never delay treatment of hypoglycemia.
3
Label every electrolyte with its dialysis timing during refeeding; post-dialysis falls are not refeeding syndrome.
4
A better HDL-C is not a better outcome. Niacin moved lipids and not events in two outcome trials.
5
Statin intolerance points to ezetimibe, bempedoic acid or PCSK9-directed therapy, chosen against kidney function, gout risk, interactions and access.
6
Nicotinamide is not niacin and not a lipid drug; its phosphate effect waned by one year in NOPHOS.

Evidence review and what changed from the blueprint

Search. PubMed (via the PubMed interface) and guideline publishers were searched on November 16, 2026, using combinations of gastrointestinal beriberi, thiamine deficiency, hemodialysis, Wernicke encephalopathy, glucagon-like peptide-1, refeeding, nicotinic acid, nicotinamide, statin intolerance, chronic kidney disease, 2PY and 4PY. Every quantitative claim was checked against the primary abstract or full text; guideline statements were checked against the guideline or its published summary tables.

What this review added or corrected. The HPS2-THRIVE primary publication DOI is 10.1056/NEJMoa1300955. The 2026 veterans cohort defined its kidney composite with a sustained ≥57% eGFR decline. The NHANES dietary niacin study also reported lower cardiovascular mortality, now shown with its limits. The AIM-HIGH CKD mortality figures were confirmed in the full text. Dose-table entries were checked against the EFNS guideline abstract, the AuSPEN full text and published reproductions of the ASPEN thiamine table; KDIGO grades were checked against the 2013 lipid guideline summary and the KDIGO 2024 graded recommendations. New sources: a 2024 systematic review of Wernicke encephalopathy in kidney disease, a 2025 hemodialysis thiamine-status study, the EFNS Wernicke guideline, the KDIGO 2013 lipid guideline summary, SHARP, and a 2024 review of vitamin supplementation in CKD, which found no randomized evidence that any vitamin supplement improves kidney, cardiovascular or patient-centered outcomes and advises individualized water-soluble vitamin supplementation.

Evidence labels. Randomized controlled trial (RCT), post hoc analysis, observational cohort, pharmacovigilance, case report and consensus are labeled where each is used. Clinical review by nephrology, pharmacy and nutrition support is required before any local order set is built from this page.

Try the CalculatorsSubukan ang mga CalculatorSulayi ang mga CalculatorSubukan ing reng Calculator
⌬
Lipid Panel Interpreter
LDL, non-HDL cholesterol and triglyceride interpretation in mg/dL or mmol/L.
Open →
⌬
AHA PREVENT 10-Year Risk
Cardiovascular risk using eGFR and urine ACR (US-derived; adults 30–79).
Open →
⌬
Statin Intolerance Aid
Structured review of statin-associated muscle symptoms (SAMS) and next options.
Open →
⌬
Malnutrition Screening in CKD
Simplified Nutritional Appetite Questionnaire (SNAQ), Malnutrition-Inflammation Score and Subjective Global Assessment (SGA) to flag nutritional risk.
Open →
⌬
Lactate Clearance
Track serial lactate after treatment starts; read beside the clinical course.
Open →
⌬
CKD-MBD Calculator
Corrected calcium, calcium–phosphate product and PTH staging for the phosphate sidebar.
Open →
Glossary & abbreviationsTalahulugan at mga daglatTalaan sa mga pulong ug daglatTalatinigan ampo reng daglat terms used in this guide

Abbreviations

4PY
N1-methyl-4-pyridone-3-carboxamide, a terminal metabolite of excess niacin.
2PY
N1-methyl-2-pyridone-5-carboxamide, a structural isomer of 4PY.
ACC/AHA
American College of Cardiology / American Heart Association.
ASCVD
Atherosclerotic cardiovascular disease.
ASPEN
American Society for Parenteral and Enteral Nutrition.
ATP
Adenosine triphosphate, the cell's energy currency.
AuSPEN
Australasian Society of Parenteral and Enteral Nutrition.
CI
Confidence interval.
CK
Creatine kinase, a muscle enzyme.
CKD
Chronic kidney disease.
CKD-MBD
Chronic kidney disease–mineral and bone disorder.
eGFR
Estimated glomerular filtration rate.
EFNS
European Federation of Neurological Societies.
FAERS
Food and Drug Administration Adverse Event Reporting System.
GLP-1 RA
Glucagon-like peptide-1 receptor agonist.
HCA2
Hydroxycarboxylic acid receptor 2 (GPR109A), the niacin receptor on fat cells.
HDL
High-density lipoprotein (the "good" cholesterol carrier).
HDL-C
High-density lipoprotein cholesterol.
HR
Hazard ratio.
IV
Intravenous.
KDIGO
Kidney Disease: Improving Global Outcomes.
LDL
Low-density lipoprotein (the "bad" cholesterol carrier).
LDL-C
Low-density lipoprotein cholesterol.
MACE
Major adverse cardiovascular events.
MAKE
Major adverse kidney events.
MRI
Magnetic resonance imaging.
NAD
Nicotinamide adenine dinucleotide, a redox cofactor made from vitamin B3.
NADH
Reduced nicotinamide adenine dinucleotide.
NHANES
National Health and Nutrition Examination Survey.
NNH
Number needed to harm.
NNT
Number needed to treat.
PCSK9
Proprotein convertase subtilisin/kexin type 9.
PDH
Pyruvate dehydrogenase.
PREVENT
Predicting Risk of cardiovascular disease EVENTs equations (American Heart Association).
PTH
Parathyroid hormone.
RCT
Randomized controlled trial.
SGA
Subjective Global Assessment.
SNAQ
Simplified Nutritional Appetite Questionnaire.
RR
Rate ratio (or relative risk).
SAMS
Statin-associated muscle symptoms.
TDP
Thiamine diphosphate (thiamine pyrophosphate), the active form of vitamin B1.
TG
Triglycerides.
VCAM-1
Vascular cell adhesion molecule 1.
WE
Wernicke encephalopathy.
α-KGDH
α-Ketoglutarate dehydrogenase.

Terms

AIM-HIGH
Randomized trial of extended-release niacin added to simvastatin in established cardiovascular disease (2011).
Beriberi
Disease of thiamine deficiency; "wet" affects the heart, "dry" the nerves, gastrointestinal beriberi the gut.
Bempedoic acid
Oral cholesterol-lowering drug that acts upstream of statins in the liver.
CLEAR Outcomes
Randomized trial of bempedoic acid in statin-intolerant patients (2023).
Ezetimibe
Drug that reduces cholesterol absorption from the gut.
Flushing
Warm, red, itchy skin, the typical side effect of nicotinic acid.
HPS2-THRIVE
Randomized trial of extended-release niacin plus laropiprant on statin therapy (2014).
Hyperlactatemia
High blood lactate; type B occurs without poor blood flow.
Laropiprant
Drug added to niacin in HPS2-THRIVE to reduce flushing.
Nicotinamide
Form of vitamin B3 (niacinamide) without cholesterol effects.
Nicotinic acid
Form of vitamin B3 that changes blood lipids at gram doses.
NOPHOS
Randomized trial of modified-release nicotinamide for high phosphate on hemodialysis.
Refeeding syndrome
Dangerous fall in phosphate, potassium or magnesium, or thiamine-related organ dysfunction, after nutrition restarts.
SHARP
Study of Heart and Renal Protection: simvastatin plus ezetimibe in CKD (2011).
Statin
Medicine that lowers LDL cholesterol by blocking its production in the liver.
Target-trial emulation
Observational analysis designed to mimic a randomized trial.
Thiamine
Vitamin B1.
Wernicke encephalopathy
Brain injury from thiamine deficiency: confusion, unsteady gait and eye movement problems.
ReferencesMga SanggunianMga TinubdanReng Reperensya 22 sources
  1. AIM-HIGH Investigators, Boden, W. E., Probstfield, J. L., Anderson, T., Chaitman, B. R., Desvignes-Nickens, P., Koprowicz, K., McBride, R., Teo, K., & Weintraub, W. (2011). Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. New England Journal of Medicine, 365(24), 2255–2267. https://doi.org/10.1056/NEJMoa1107579
  2. Baigent, C., Landray, M. J., Reith, C., Emberson, J., Wheeler, D. C., Tomson, C., Wanner, C., Krane, V., Cass, A., Craig, J., Neal, B., Jiang, L., Hooi, L. S., Levin, A., Agodoa, L., Gaziano, M., Kasiske, B., Walker, R., Massy, Z. A., ... Collins, R. (2011). The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial. Lancet, 377(9784), 2181–2192. https://doi.org/10.1016/S0140-6736(11)60739-3
  3. Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., de Ferranti, S. D., Gianos, E., Gluckman, T. J., Gradney, K. F., Isiadinso, I., Lloyd-Jones, D. M., Marrs, J. C., Martin, S. S., McLain, K. H., Mehta, L. S., ... Wilkins, J. T. (2026). 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of dyslipidemia: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 153(17), e1154–e1276. https://doi.org/10.1161/CIR.0000000000001423
  4. Campos, L. M., Nogueira, R. J. N., Tresoldi das Neves Romaneli, M., Farias, M. G. O., & Bustorff-Silva, J. (2026). Abdominal pain and hyperlactatemia in thiamine deficiency: A case report. Case Reports in Pediatrics, 2026, 4401612. https://doi.org/10.1155/crpe/4401612
  5. da Silva, J. S. V., Seres, D. S., Sabino, K., Adams, S. C., Berdahl, G. J., Citty, S. W., Cober, M. P., Evans, D. C., Greaves, J. R., Gura, K. M., Michalski, A., Plogsted, S., Sacks, G. S., Tucker, A. M., Worthington, P., Walker, R. N., & Ayers, P. (2020). ASPEN consensus recommendations for refeeding syndrome. Nutrition in Clinical Practice, 35(2), 178–195. https://doi.org/10.1002/ncp.10474
  6. Day, B. D., Lever, J. E. P., Vickers, K., & Centor, R. (2026). Gastrointestinal beriberi secondary to intermittent hemodialysis with rapid improvement following thiamine administration. Case Reports in Gastrointestinal Medicine, 2026, 3195006. https://doi.org/10.1155/crgm/3195006
  7. Ferrell, M., Wang, Z., Anderson, J. T., Li, X. S., Witkowski, M., DiDonato, J. A., Hilser, J. R., Hartiala, J. A., Haghikia, A., Cajka, T., Fiehn, O., Sangwan, N., Demuth, I., König, M., Steinhagen-Thiessen, E., Landmesser, U., Tang, W. H. W., Allayee, H., & Hazen, S. L. (2024). A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk. Nature Medicine, 30(2), 424–434. https://doi.org/10.1038/s41591-023-02793-8
  8. Galvin, R., Bråthen, G., Ivashynka, A., Hillbom, M., Tanasescu, R., & Leone, M. A. (2010). EFNS guidelines for diagnosis, therapy and prevention of Wernicke encephalopathy. European Journal of Neurology, 17(12), 1408–1418. https://doi.org/10.1111/j.1468-1331.2010.03153.x
  9. HPS2-THRIVE Collaborative Group, Landray, M. J., Haynes, R., Hopewell, J. C., Parish, S., Aung, T., Tomson, J., Wallendszus, K., Craig, M., Jiang, L., Collins, R., & Armitage, J. (2014). Effects of extended-release niacin with laropiprant in high-risk patients. New England Journal of Medicine, 371(3), 203–212. https://doi.org/10.1056/NEJMoa1300955
  10. Kalil, R. S., Wang, J. H., de Boer, I. H., Mathew, R. O., Ix, J. H., Asif, A., Shi, X., & Boden, W. E. (2015). Effect of extended-release niacin on cardiovascular events and kidney function in chronic kidney disease: A post hoc analysis of the AIM-HIGH trial. Kidney International, 87(6), 1250–1257. https://doi.org/10.1038/ki.2014.383
  11. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. (2024). KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International, 105(4S), S117–S314. https://doi.org/10.1016/j.kint.2023.10.018
  12. Ketteler, M., Wiecek, A., Rosenkranz, A. R., Ose, C., Rekowski, J., Lorenz, H., Hellmann, B., Karus, M., Ruhmann, M., & Ammer, R. (2023). Modified-release nicotinamide for the treatment of hyperphosphataemia in haemodialysis patients: 52-week efficacy and safety results of the phase 3 randomized controlled NOPHOS trial. Nephrology Dialysis Transplantation, 38(4), 982–991. https://doi.org/10.1093/ndt/gfac206
  13. Lev, D., Leibowitz, A., Lang, A., Shlomai, G., Twig, G., Eden-Friedman, Y., Engel, T., Cukierman-Yaffe, T., Dankner, R., Gerstein, H. C., & Goldman, A. (2026). Glucagon-like peptide-1 receptor agonists and Wernicke encephalopathy: A pharmacovigilance study and literature review. Clinical Nutrition, 57, 106571. https://doi.org/10.1016/j.clnu.2025.106571
  14. Matthews-Rensch, K., Blackwood, K., Lawlis, D., Breik, L., McLean, C., Nguyen, T., Phillips, S., Small, K., Stewart, T., Thatcher, A., Venkat, L., Brodie, E., Cleeve, B., Diamond, L., Ng, M. Y., Small, A., Viner Smith, E., & Asrani, V. (2025). The Australasian Society of Parenteral and Enteral Nutrition: Consensus statements on refeeding syndrome. Nutrition & Dietetics, 82(2), 128–142. https://doi.org/10.1111/1747-0080.70003
  15. Naim, M. A. A. Z., Thomas, F., Streja, E., Davis, R. L., Kalantar-Zadeh, K., Sumida, K., & Kovesdy, C. P. (2026). Renal outcomes of triglyceride-targeting lipid-lowering therapies versus statins in patients with CKD. Clinical Journal of the American Society of Nephrology, 21(11), 1914–1927. https://doi.org/10.2215/CJN.0000001188
  16. Nissen, S. E., Lincoff, A. M., Brennan, D., Ray, K. K., Mason, D., Kastelein, J. J. P., Thompson, P. D., Libby, P., Cho, L., Plutzky, J., Bays, H. E., Moriarty, P. M., Menon, V., Grobbee, D. E., Louie, M. J., Chen, C. F., Li, N., Bloedon, L., Robinson, P., ... Nicholls, S. J. (2023). Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. New England Journal of Medicine, 388(15), 1353–1364. https://doi.org/10.1056/NEJMoa2215024
  17. Oudman, E., Wijnia, J. W., Severs, D., Oey, M. J., van Dam, M., van Dorp, M., & Postma, A. (2024). Wernicke's encephalopathy in acute and chronic kidney disease: A systematic review. Journal of Renal Nutrition, 34(2), 105–114. https://doi.org/10.1053/j.jrn.2023.10.003
  18. Rosewarne, R. E., & Farina, N. (2026). Thiamine use in hospitalized patients: A clinical review. Journal of Nutrition and Metabolism, 2026, 7143046. https://doi.org/10.1155/jnme/7143046
  19. Wang, A. Y., Elsurer Afsar, R., Sussman-Dabach, E. J., White, J. A., MacLaughlin, H., & Ikizler, T. A. (2024). Vitamin supplement use in patients with CKD: Worth the pill burden? American Journal of Kidney Diseases, 83(3), 370–385. https://doi.org/10.1053/j.ajkd.2023.09.005
  20. Wanner, C., & Tonelli, M. (2014). KDIGO clinical practice guideline for lipid management in CKD: Summary of recommendation statements and clinical approach to the patient. Kidney International, 85(6), 1303–1309. https://doi.org/10.1038/ki.2014.31
  21. Yang, B., Lan, N., Zeng, F., Shao, Q., Ye, D., Wang, H., Xue, C., & Liu, N. (2025). Assessment of thiamine status and its association with clinical parameters in patients undergoing maintenance hemodialysis. Frontiers in Nutrition, 12, 1563768. https://doi.org/10.3389/fnut.2025.1563768
  22. Zhang, D., Wu, H., Gong, S., Zhou, G., Liu, Y., Li, Y., & Yang, X. (2025). The generalized association between niacin intake and cardiovascular events in US adults living with chronic kidney disease. International Journal for Vitamin and Nutrition Research, 95(4), 37256. https://doi.org/10.31083/IJVNR37256
Dr. W Rivero, MD

W Rivero, MD, FPCP, DPSN

Specialist in Internal Medicine, Nephrology, and Clinical Nutrition. Practicing integrative and evidence-based nephrology across Quezon City, Pampanga, and Bulacan.

· Book an Appointment →

QR code — scan to save Dr. Rivero's contact info